TuBerculosis Vaccine Initiative (www.tbvi.eu), a unique product development partnership (PDP) in the field of TB vaccine R&D, is recruiting an early to mid-career dynamic person for the [...]
The Norwegian Agency for Development Cooperation (Norad) has commissioned the Norwegian Institute of Public Health (NIPH) to conduct a review of the Norwegian Ministry of Foreign Affairs [...]
On March 25th, 2015 – a day after the world commemorated the progress we’ve made against tuberculosis (TB), the 2015 Spring Meeting of the Biomarkers and Correlates Working Group (BCWG) was held. [...]
Fourth Global Forum on TB Vaccines Held April 21-24, 2015 SHANGHAI (1 May, 2015) – Nearly 300 experts in tuberculosis (TB) and TB vaccine development from 32 countries around the world gathered [...]
A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting [...]
The Governance Board of TBVI is pleased to announce the following senior leadership appointments: The Executive Director of TBVI is Dr Nick Drager, previously Chair of the TBVI Advisory [...]
The TBVI consortium has been granted 24.6 million euros from the European Commission H2020 framework programme (€18.2 mln.) and several institutions as well as national governments outside the [...]
TBVI is partner in ADITEC, a project to advance new immunisation technologies. Partners of this consortium are presenting the fourth course on adjuvants and vaccine formulation. Dates: 15-19 June [...]
Runderweg 6
8219 PK Lelystad
The Netherlands
Email: info@tbvi.eu
Phone: +31 320 277 550
